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BioPsies of the peripheral nervous system are frequent and often per-formed with the aim to investigate the disease process in some patients. However, due to the extremely invasive nature of the procedure, bi-
opsies of the central nervous system (CNs) are performed only in special and 
rare circumstances. This inability to explore the brain of a living individual 
limits considerably our knowledge about the advance of neurodevelopmental 
and neurodegenerative diseases. Most of our current knowledge about cellular 
phenotypes related to CNs diseases in humans was gathered from studies per-
formed in brain tissue collected postmortem, which is not necessarily preserved 
appropriately. Moreover, in most cases the tissues represent only the end-stage 
of the disease, eliminating the possibility of exploring the initial events respon-
sible for the cascade of cellular changes that lead to the final result, be it struc-
tural changes or even cell death.
Animal models are extremely useful because they can reproduce vari-
ous forms of human genetic neurodegenerative diseases. Transgenic models or 
knockouts have produced numerous insights into new molecular mechanisms 
behind many human diseases, creating new possibilities for therapeutic inter-
vention. Currently, these models are restricted to monogenetic diseases, limit-
ing the use range and representing only a small number of human diseases that 
can be modeled. Technical difficulties, interspecies differences and differences in 
genetic backgrounds end up interfering in the animal model process, even in the 
case of monogenetic diseases. in many cases, transgenic or knockout technology 
is incapable of reproducing human symptoms in animals, indicating a clear need 
for human models.
The original cell reprogramming experiments led by Japanese researcher 
shinya Yamanaka surprised the scientific community by breaking the dogma 
that specialized cells in the human body would have a lifetime identity (Taka-
hashi et al., 2007). The forced expression of a group of transcription factors, 
genes related to the pluripotent state, has the ability to redirect the identity of 
specialized cells and represents a superb way to demonstrate cellular flexibility. 
This induced return to the pluripotent embryonic stage was dubbed iPsC (in-
duced Pluripotent stem Cells).
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Concisely, gene reprogramming involves the return to a more potent and 
plastic form from an already differentiated or specialized cell. for example, the 
skin cell of an adult can be transformed into an unspecialized, undifferentiated 
cell, capable of dividing indefinitely. This undifferentiated and immortal cell 
would have the potential to specialize again in the same skin cell or in any other 
cell type, including a neuron. in summary, it is possible to obtain embryonic-
like stem cells on demand, using the same genetic material of the patient and 
avoiding possible rejection in case of transplants.
Although the idea of a transplant without rejection is extremely attractive 
to those interested in a possible cell therapy, Yamanaka’s experiments enable 
turning into reality the dream of many neuroscientists: to capture the human 
genome of a patient in pluripotent stem cells and use them for unlimited pro-
duction of specialized cells of the nervous system (Muotri, 2009). Although 
iPsC generated from the patient are, in theory, less immunogenic for possible 
transplant therapies, the focus of this article is geared toward future clinical ap-
plications of this technology in vitro, such as modeling neurological diseases and 
using biotechnology for the discovery of novel drugs through drug screening.
iPSC generated from human neurodegenerative diseases
Diseases that can be modeled by cellular reprogramming may be rare, mono-
genetic or in the broad spectrum of sporadic and multifactorial diseases. To date, 
there is no scientific publication demonstrating the usefulness of iPsC technology 
to model the latter group of complex diseases. The difficulty to obtain conclusive 
results from this type of complex illness is possibly due to different genetic back-
grounds and environmental/epigenetic influences. it is worth noting that even 
monogenetic diseases can show a large phenotypic variability. it will be necessary 
to determine whether the genotype-phenotype variation observed in patients will 
be reproduced by neurons generated from the patients’ iPsC or if reprogramming 
will eliminate the epigenetic or environmental “noise”.
Reprogramming of somatic cells has been published for some neurologi-
cal diseases. However, a critical reading reveals that few studies have actually 
shown that it is possible to recapitulate the human phenotype in iPsC-derived 
neurons. The derivation of neurons from iPsC has been described for sporadic 
forms of neurodegenerative diseases with late symptoms such as amyotrophic 
lateral sclerosis (ALs) and Parkinson’s disease (Park et al. 2008; soldner et al. 
2009; Dimos et al. 2008). from the reprogramming point of view, it is remark-
able that aged fibroblasts (up to 85 years old) from ALs and PD patients could 
still be reset with similar efficiency as fibroblasts from younger patients. Despite 
the excitement generated by these early studies, none of them showed pheno-
types related to the disease in affected cells. it is possible that cellular pheno-
types will arise only over the years, precisely as it happens in the patients’ bodies. 
This would make the process highly ineffective due to the technical difficulties 
of maintaining functional neurons in culture for such a long time. identifying 
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situations that mimic premature aging, for example, by culturing cells under 
increased oxidative stress seems to be a creative solution.
Partial modeling with the spontaneous phenotype generation in the labo-
ratory was observed for two monogenetic diseases with early symptoms: spinal 
muscular atrophy (sMA) and familial dysautonomia (fD) (ebert et al., 2009; 
Lee et al., 2009). Both are autosomal recessive diseases, which have in common 
the rapid progression in the early years of life. in addition, both diseases are 
associated with loss of function of genes involved in RNA processing. sMA rep-
resents a group of recessive disorders caused by deletions or mutations in sMN 
(survival Motor Neuron) genes. The sMN1 gene encodes a protein involved in 
RNA processing (Lorson et al. 1998). sMA type 1 is characterized by mutations 
in the sMN1 gene, leading to a rapid degeneration of motor neurons, which 
results in severe muscle atrophy. The symptoms appear around six months of 
age and the patient’s death occurs by respiratory disability before the age of 
two. iPsC cells from a single sMA patient have been characterized and differen-
tiated into motor neurons. When compared to iPsC-generated motor neurons 
from a healthy maternal control (non-carriers of the disease), it was found that 
the sMA-iPsC generated a small number of motor neurons, suggesting the 
premature death of this cell type. The study does not provide a functional char-
acterization of the motor neurons generated by the group (ability to stimulate 
potentials or action or form neuromuscular junctions). The group also observed 
an increase in the number of protein aggregates known as “gems” in fibroblasts 
and iPsC from the sMA patient. These gems are often directly associated with 
disease intensity. The aggregates were converted into fibroblasts or sMA-iPsC 
with the use of specific drugs. Unfortunately, the group did not analyze the 
presence of these gems in the cells of interest, i.e., the motor neurons. This 
study showed for the first time a proof of principle that iPsC can be used as a 
future platform for screening drugs that can reverse or mitigate cellular pheno-
types associated with human diseases.  Unfortunately, the initial enthusiasm was 
cooled by the absence of stringer controls and other sMA patients. incorpora-
tion of additional control, loss and gain of function would have appeased the 
concern that the observed phenotype would be a consequence of the intrinsic 
iPsC variability system (discussed next).
fD is also a recessive disease that occurs at increased frequency in individu-
als of Ashkenazi Jewish descent (Brunt & McKusick, 1970). The disease is char-
acterized by degeneration of sensory and autonomic neurons, leading to severe 
and lethal general dysfunction. Clinical features include alacrima, hypoactivity and 
relative indifference to pain and temperature. A splicing defect in the iKBKAP 
gene results in a tissue-specific loss of protein function (slaugenhaupt et al. 2001). 
iPsC derived from three fD patients were differentiated into progenitor cells and 
revealed low levels of iKBKAP expression when compared to the control group. 
Defects in neuronal differentiation and migration were also observed in iPsC-fD-
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derived neural progenitor cells. A drug (kinetin) was used to partly recover mu-
tant IKBKAP RNA splicing in these cells, reversing the migration defects but not 
neuronal differentiation defects. Kinetin chemical variations could have been used 
in an attempt to reverse both defects. Anyway, this second study has advantages 
over the first, particularly because it includes more than one patient.
Modeling neurodevelopmental disorders
Although advances in iPsC modeling have been restricted thus far to 
neurodegenerative diseases, i anticipate that the technology will be useful for 
modeling neurodevelopmental and psychiatric disorders such as autism and 
schizophrenia. However, i believe that initial results will probably emerge from 
monogenetic, early-onset diseases of known causes. An example of a human 
disease with great modeling potential is Rett syndrome, which is characterized 
by arrested development in early childhood, regression of acquired skills, loss 
of speech, stereotypical movements, and a broad range of autistic characteristics 
(samaco et al. 2005). Rett female patients are generally heterozygous for muta-
tions in the X-linked MeCP2 gene. MeCP2 protein shows higher affinity for 
methylated DNA and seems to be involved in epigenetic regulation of target 
genes in the nervous system. Knowing the gene involved in this syndrome will al-
low genetic manipulation in iPsC-derived neurons from patients with Rett syn-
drome, validating any cellular or molecular phenotypes found after differentia-
tion. This important validation will be essential to convince us that the observed 
phenotypes are not the result of experimental variations.
Rett syndrome is one of the syndromes associated with AsD and perhaps 
the ideal prototype to start investigating complex psychiatric diseases. following 
this model, the next step would be to seek similar phenotypes in several AsD 
syndromes, seeking common molecular pathways. A major challenge for this 
category of disorders would lie in distinguishing the contribution of genetic 
background and environmental factors. New tools for the genetic manipulation 
of pluripotent stem cells, such as homologous recombination and the use of 
specific zinc-finger endonucleases, may help to eliminate noise or experimental 
variability (Zwaka & Thomson 2003; Hockemeyer et al. 2009). An alternative 
for revealing complex and neuronal phenotypes and specific neural behaviors 
could be the use of chimeric animals. Human embryonic stem cells transplanted 
into the brain of murine embryos revealed the enormous adaptation potential of 
pluripotent cells as a result of contact with the cell niche (Muotri et al., 2005). 
This type of modeling puts together the human cellular genetic background 
and the manipulation of an animal body, thus enabling studying the effects of 
environmental changes in human neurons.
Using human neurons                                                                                                                                          
as a tool for screening new drugs
in the past, drug candidates were selected using human cell strains and 
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represented a great advance in medicine. An example was the development of 
polio vaccines, originally based developed in vitro, using the HeLa cell strain 
(syverton  et al., 1954). Patient-derived iPsC can offer a much bigger advan-
tage in relation to the traditional transformed cell line model, as they take into 
consideration the donor’s original genome and have the ability to differentiate 
the specific cell type affected at the exact time of development.
one of the great benefits of reprogramming cells is the possibility of study-
ing the developmental steps of progenitor neural cells before they completely 
mature into functional neurons. Neural progenitor cells can give rise to both 
glial and neuronal populations. These populations can further differentiate into 
specific subtypes of neurons, for example, generating various cell types respon-
sible for the development and formation of the brain (Muotri & Gage, 2006). it 
is very likely that some diseases affect only a specific subtype of neuron that has 
its origins back in the precursor phase. in these cases, therapeutic interventions 
should occur at the exact stage of development. in addition to these advantages, 
iPsC provide the unique opportunity for testing drugs directly in human neural 
networks, something that was hardly imagined a few years ago.
The observation of cell phenotypes during drug screening can greatly ben-
efit from well-established neuroscience techniques. The analysis of single cells 
can involve neuronal morphology, branching, polarity, neuronal spine density 
and maturation time. Likewise, electrophysiology can be used to demonstrate 
communication between two cells. Non-autonomous effects, such as astrocytes 
influence can also be studied after iPsC differentiation and co-culturing with 
more than one cell type. some differentiation protocols for certain subtypes 
of neurons already exist, but we still do not know how to differentiate iPsC in 
culture in all cell types in the human brain. Direct conversion from somatic cells 
or even from iPsC-derived neural progenitors may be an alternative and can be 
achieved with a of specific transcription factor cocktail for each cell type. once 
obtained, these protocols will enable establishing neuronal circuits in culture, a 
step forward for understanding diseases and testing new drugs.
once a consistent cell phenotype is identified in a patient’s iPsC-derived 
neurons, drug testing platforms can be developed with the aim of testing new 
drugs capable of reversing or alleviate the neuronal defect. After several tests 
under different experimental conditions, new therapeutic compounds could 
emerge, benefiting many patients (figure 1).
The intrinsic variability of pluripotent stem cells
Available human embryonic stem cells vary considerably in relation to 
epigenetic markers, gene expression profile and differentiation propensity (osa-
fune et al., 2008). Apparently, iPsC behave similarly, offering the same intrinsic 
variability spectrum (Pick et al. 2009). The differences in gene expression pro-
file are generally attributed to the introduction of reprogramming vectors that 
integrate randomly into the genome, or even to the continued expression of 
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pluripotent cDNAs used in the process. An alternative explanation generated 
from reprogramming without the use of viral vectors suggests retention of the 
genetic “memory” of the cell type that it once was (Marchetto et al., 2009). The 
reason for the variation is still an open question, and more data will be needed 
for the formulation of hypotheses to be tested. Anyway, this is still a very im-
portant point for defining the level of variability among different iPsC clones 
generated from the same individual. This type of information is essential for the 
establishment of strict controls during the definition of cell phenotypes.
Conclusions
scientists around the world are using iPsC technology to investigate to 
early stages of human development and to model neurological diseases. so far, 
this technique has been shown to be restricted to monogenetic diseases, reveal-
ing a work methodology for elucidating new molecular pathways responsible for 
human pathologies. Modeling late-onset diseases such as Alzheimer’s, or even 
psychiatric disorders like autism will require additional factors for the system to 
be challenged and reveal relevant cellular phenotypes. The potential of cell re-
programming seems to be indeed limited by human creativity and ethical princi-
ples defined by society. Neuroscientists in the past could not imagine a scenario 
in which endless nerve cells of living patients could be constantly generated and 
studied in laboratories around the world. in turn, researchers in the future will 
not be able to imagine science without such a tool. Time alone will tell.
figure 1 – Modeling of neurological diseases using iPsC technology. Reprogramming 
of somatic cells of patients and controls, generating isogenic iPsC, i.e., 
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subtypes of neurons in accordance with the target cell for each disease. 
Cellular phenotypes are assessed by measuring neuronal morphology, e.g., 
soma size, number of processes, etc. Next, connectivity and circuitry inte-
gration in culture can be analyzed by different methods well established in 
neurosciences, such as electrophysiology. in addition, cross talk between 
neurons and glia can be studied in co-cultures to tease out autonomous 
events of secondary phenotypes in each type of human disease. once the 
phenotype is identified, drug-screening platforms to revert of attenuate 
the phenotype can be used. New therapies and drugs can emerge from 
this approach, benefiting numerous neurological patients. Adapted from 
Marchetto et al. 2010.
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AbstRAct – Most of our current knowledge about cellular phenotypes related to neu-
rological diseases was gathered from studies performed in brain tissue collected post-
-mortem. These samples often represent the end-stage of the disease process and may 
not represent a fair picture of how the disease developed over time. furthermore, under 
these conditions, the pathology may as well be a secondary effect of the disease process 
or even due to the poor tissue condition and may not represent an authentic cellular 
phenotype. Likewise, animal models not always recapitulate the pathology from human 
disorders.  in this article, i will present a critical view on the recent advances obtained 
from disease modeling using human pluripotent stem cells. The focus on cellular re-
programming as a tool to generate patient-specific induced pluripotent stem cells is 
justified by the great experimental potential, not only for disease modeling, but also as 
a biotechnological tool for future drug-screening platforms and personalized medicine.
KeywoRds: Pluripotent stem cells, Cellular reprogramming, Neurological diseases, 
Drug-screening.
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